Top Active Trader Alert Stocks (CLDA, GXDX, NVDA, OCCF, TSLA)

Investing

Published: January 24, 2011 8:52 am

Active traders and day traders have many stocks to choose from this Monday morning. We are tracking news and moves in shares of Clinical Data, Inc. (NASDAQ: CLDA), Genoptix, Inc. (NASDAQ: GXDX), NVIDIA Corporation (NASDAQ: NVDA), Optical Cable Corporation (NASDAQ: OCCF), and Tesla Motors Inc. (NASDAQ: TSLA).

Clinical Data, Inc. (NASDAQ: CLDA) is up 56% to $24.49, relative to a 52-week range of $10.87-$22.39. The company has announced that the FDA has approved one of its drugs, intended to treat depression.

Genoptix, Inc. (NASDAQ: GXDX) is up more than 25% premarket to $24.88, relative to a 52-week range of $13.51-$39.00. The company has announced that it has closed a deal to be acquired by Novartis International AG.

NVIDIA Corporation (NASDAQ: NVDA) is up 4.46% premarket to $23.21, relative to a 52-week range of $8.65-$23.98.

Optical Cable Corporation (NASDAQ: OCCF) is up roughly 16% to $4.34, above a 52-week range of $2.16-$4.01.

Tesla Motors Inc. (NASDAQ: TSLA) is up 3.3% premarket to $23.80, relative to a 52-week range of $14.98-$36.42. JP Morgan recently reiterated TSLA as overweight.

Get Ready To Retire ^(Sponsored)

Start by taking a quick retirement quiz from SmartAsset that will match you with up to 3 financial advisors that serve your area and beyond in 5 minutes, or less.

Each advisor has been vetted by SmartAsset and is held to a fiduciary standard to act in your best interests.

Here’s how it works:
1. Answer SmartAsset advisor match quiz
2. Review your pre-screened matches at your leisure. Check out the advisors’ profiles.
3. Speak with advisors at no cost to you. Have an introductory call on the phone or introduction in person and choose whom to work with in the future

Have questions about retirement or personal finance? Email us at [email protected]!

By emailing your questions to 24/7 Wall St., you agree to have them published anonymously on a673b.bigscoots-temp.com.

By submitting your story, you understand and agree that we may use your story, or versions of it, in all media and platforms, including via third parties.